Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.41 |
| ▸ | REN | P00797 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PEPD | P12955 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28261258 | 1.00 | ACE (0.41) | ACERENLMNAHSD17B10MAPT | |
| SCHEMBL24162042 | 0.83 | DPP4 (0.36) | ACERENLMNAHSD17B10MAPT | |
| SCHEMBL5695504 | 0.82 | PIK3CA (0.34) | LMNAKDM4E | |
| SCHEMBL9456502 | 0.82 | PIK3CA (0.34) | LMNAKDM4E | |
| SCHEMBL28267035 | 0.80 | ACE (0.43) | ACERENLMNAHSD17B10MAPT | |
| SCHEMBL10906984 | 0.79 | ACE (0.41) | ACERENLMNAHSD17B10MAPT | |
| SCHEMBL23077176 | 0.79 | BCHE (0.35) | KDM4E | |
| SCHEMBL6535156 | 0.76 | LMNA (0.43) | ACERENLMNAHSD17B10MAPT | |
| SCHEMBL9230240 | 0.76 | ACE (0.40) | ACERENLMNAHSD17B10MAPT | |
| SCHEMBL9853736 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108852993-A | Moisturizing beautifying liquid | 常州市长昊机械有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108852993-A | Moisturizing beautifying liquid | 常州市长昊机械有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| EP-2041138-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008005956-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | ACE 415/4885REN 2855/4885LMNA 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.